简介：

简介：

简介：无

简介：内容摘要：本文首先介绍了MDS算法在消息摘要产生过程中的应用的开发背景和实际意义。系统采用的开发工具为：Dreamweaver、ASP;Dreamweaver进行前台界面设计，ASP语言实现MD5消息摘要算法来对一个消息产生消息摘要、及使用RSA加密算法对一个消息或消息摘要进行数字签名。其次介绍了该系统内主要功能模块的分析及设计。

简介：内容摘要：本文首先介绍了MDS算法在消息摘要产生过程中的应用的开发背景和实际意义。系统采用的开发工具为：Dreamweaver、ASP;Dreamweaver进行前台界面设计，ASP语言实现MD5消息摘要算法来对一个消息产生消息摘要、及使用RSA加密算法对一个消息或消息摘要进行数字签名。其次介绍了该系统内主要功能模块的分析及设计。

简介：摘要：本文首先介绍了MDS算法在消息摘要产生过程中的应用的开发背景和实际意义。系统采用的开发工具为：Dreamweaver、ASP;Dreamweaver进行前台界面设计，ASP语言实现MD5消息摘要算法来对一个消息产生消息摘要、及使用RSA加密算法对一个消息或消息摘要进行数字签名。其次介绍了该系统内主要功能模块的分析及设计。

简介：AbstractLimited data is available on the coronavirus disease 2019 (COVID-19), critical illness rate, and in-hospital mortality in the African setting. This study investigates determinants of critical illness and in-hospital mortality among COVID-19 patients in Kenya. We conducted a retrospective cohort study at Kenyatta National Hospital (KNH) in Kenya. Multivariate logistic regression and Cox proportional hazard regression were employed to determine predictor factors for intensive care unit (ICU) admission and in-hospital mortality, respectively. In addition, the Kaplan-Meier model was used to compare the survival times using log-rank tests. As a result, 346 (19.3%) COVID-19 patients were admitted to ICU, and 271 (15.1%) died. The majority of those admitted to the hospital were male, 1,137 (63.4%) and asymptomatic, 1,357 (75.7%). The most prevalent clinical features were shortness of breath, fever, and dry cough. In addition, older age, male, health status, patient on oxygen (O2), oxygen saturation levels (SPO2), headache, dry cough, comorbidities, obesity, cardiovascular diseases (CVDs), diabetes, chronic lung disease (CLD), and malignancy/cancer can predicate the risk of ICU admission, with an area under the receiver operating characteristic curve (AUC-ROC) of 0.90 (95% confidence interval [CI]: 0.88-0.92). Survival analysis indicated 271 (15.1%) patients died and identified older age, male, headache, shortness of breath, health status, patient on oxygen, SPO2, headache, comorbidity, CVDs, diabetes, CLD, malignancy/cancer, and smoking as risk factors for mortality (AUC-ROC: 0.90, 95% CI: 0.89-0.91). This is the first attempt to explore predictors for ICU admission and hospital mortality among COVID-19 patients in Kenya.

简介：无

简介：AbstractForecasting the COVID-19 confirmed cases, deaths, and recoveries demands time to know the severity of the novel coronavirus. This research aims to predict all types of COVID-19 cases (verified people, deaths, and recoveries) from the deadliest 3rd wave data of the COVID-19 pandemic in Bangladesh. We used the official website of the Directorate General of Health Services as our data source. To identify and predict the upcoming trends of the COVID-19 situation of Bangladesh, we fit the Auto-Regressive Integrated Moving Average (ARIMA) model on the data from Mar. 01, 2021 to Jul. 31, 2021. The finding of the ARIMA model (forecast model) reveals that infected, deaths, and recoveries number will have experienced exponential growth in Bangladesh to October 2021. Our model reports that confirmed cases and deaths will escalate by four times, and the recoveries will improve by five times at a later point in October 2021 if the trend of the three scenarios of COVID-19 from March to July lasts. The prediction of the COVID-19 scenario for the next three months is very frightening in Bangladesh, so the strategic planner and field-level personnel need to search for suitable policies and strategies and adopt these for controlling the mass transmission of the virus.

简介：【摘要】目的 观察早期活动对危重症机械通气患者ICU获得性衰弱(ICU-AW)的影响。方法 将本院重症医学科2020年7月到2021年8月所收治的70例患者作为本次研究对象，随机将所有患者分为常规组和实验组，每组35例。常规组实施传统护理干预，实验组进行早期活动干预，对比两组的ICU获得性衰弱评分和护理满意度。结果 护理后，实验组的ICU获得性衰弱评分改善情况和总体护理满意度，都优于常规组，差异性明显（P

简介：AbstractThe impact of coronavirus disease 2019 (COVID-19) on endometriosis (EM) is currently unclear. Here, we aimed to describe the potential influence of COVID-19 on the pathogenesis, clinical symptoms, and treatment of EM. The cytokine storm caused by COVID-19 may induce the occurrence and progression of EM, and immunosuppression of COVID-19 may help the ectopic endometrium escape from immune clearance. Consequently, the forced social isolation and the cancelation of non-emergency medical treatment during the COVID-19 pandemic aggravate anxiety and psychological pressure, which can aggravate the symptoms related to EM and delay routine medical services.

简介：无

简介：无

简介：AbstractBackground:To date, there is no effective medicine to treat coronavirus disease 2019 (COVID-19), and the antiviral efficacy of arbidol in the treatment for COVID-19 remained equivocal and controversial. The purpose of this study was to evaluate the efficacy and safety of arbidol tablets in the treatment of COVID-19.Methods:This was a prospective, open-label, controlled and multicenter investigator-initiated trial involving adult patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Patients were stratified 1:2 to either standard-of-care (SOC) or SOC plus arbidol tablets (oral administration of 200 mg per time, three times a day for 14 days). The primary endpoint was negative conversion of SARS-CoV-2 within the first week. The rates and 95% confidential intervals were calculated for each variable.Results:A total of 99 patients with laboratory-confirmed SARS-CoV-2 infection were enrolled; 66 were assigned to the SOC plus arbidol tablets group, and 33 to the SOC group. The negative conversion rate of SARS-CoV-2 within the first week in patients receiving arbidol tablets was significantly higher than that of the SOC group (70.3% [45/64] vs. 42.4% [14/33]; difference of conversion rate 27.9%; 95% confidence interval [CI], 7.7%-48.1%; P = 0.008). Compared to those in the SOC group, patients receiving arbidol tablets had a shorter duration of clinical recovery (median 7.0 days vs. 12.0 days; hazard ratio [HR]: 1.877, 95% CI: 1.151-3.060, P = 0.006), symptom of fever (median 3.0 days vs. 12.0 days; HR: 18.990, 95% CI: 5.350-67.410, P < 0.001), as well as hospitalization (median 12.5 days vs. 20.0 days; P < 0.001). Moreover, the addition of arbidol tablets to SOC led to more rapid normalization of declined blood lymphocytes (median 10.0 days vs. 14.5 days; P > 0.05). The most common adverse event in the arbidol tablets group was the elevation of transaminase (5/200, 2.5%), and no one withdrew from the study due to adverse events or disease progression.Conclusions:SOC plus arbidol tablets significantly increase the negative conversion rate of SARS-CoV-2 within the first week and accelerate the recovery of COVID-19 patients. During the treatment with arbidol tablets, we find no significant serious adverse events.Trial registration:Chinese Clinical Trial Registry, NCT04260594, www.clinicaltrials.gov/ct2/show/NCT04260594?term= NCT04260594&draw=2&rank=1

简介：摘要由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的2019年冠状病毒疾病（COVID-19）已经在全球多个国家引起大流行，该病毒传染性强、致死率高，部分变异株在病毒传播性、致病性和免疫原性等多方面发生变化。无症状感染和有症状感染的COVID-19患者在免疫特征上存在异质性；不同年龄阶段的COVID-19患者的临床表现也不尽相同。目前无治疗COVID-19的特效药物，疫情控制需依赖新型冠状病毒疫苗的接种，如核酸疫苗、灭活疫苗、病毒载体疫苗、蛋白质疫苗等。本文通过对新型冠状病毒的变异、临床表现、治疗和疫苗等方面文献的复习，展现目前相关研究的进展。

简介：AbstractA large-scale vaccination of coronavirus disease-19 (COVID-19) in adults has been conducted for nearly a year, and there is a growing recognition that immunization for children is also essential. It has been months since emergency use of pediatric COVID-19 vaccine was approved, we reviewed the prevalence and transmission of COVID-19 in children. The prevalence of COVID-19 in children is reduced due to vaccination even in a Delta prevalent period, so an increase in the vaccination rate is needed in children. Although the precise role of children in the transmission requires more research to uncover, they likely played a significant role, according to the available literature. We also described four candidate COVID-19 vaccines for children on their safety and immunogenicity and the impact of severe acute respiratory syndrome coronavirus 2 variants on childhood vaccination. Safety issues on pediatric vaccines post-approval, like adverse events following immunization and adverse events of special interest require studies on long-term and effective regulatory mechanisms.

简介：无

简介：无

简介：AbstractCOVID-19 has been a global health concern since 2019 until date. Global concerted efforts to combat this pandemic has resulted in a number of vaccines distributed across the globe. Although the presence of these vaccines produced quick interventions, dynamic mutation in the causal virus and the continuous evolution of new stains that defy available vaccines has given rise to pertinent questions. The most recent emergence of a new COVID-19 virus variant (omicron), the rapid spread and overwhelming rate of morbidity and mortality has reopened these questions for debate. This commentary summarizes major view on these questions and concludes that multiple approach including social behavioural measures, vaccination and antiviral drug would speed up elimination process.

简介：AbstractObjective:Otolaryngologists are at increased occupational risk of Coronavirus Disease 2019 (COVID-19) infection due to exposure from respiratory droplets and aerosols generated during otologic, nasal, and oropharyngeal examinations and procedures. There have been a variety of guidelines and precautions developed to help mitigate this risk. While many reviews have focused on the personal protective equipment (PPE) and preparation guidelines for surgery in the COVID-19 era, none have focused on the more creative and unusual solutions designed to limit viral transmission. This review aims to fill that need.Data Sources:PubMed, Ovid/Medline, and ScopusMethods:A comprehensive review of literature was performed on September 28, 2020 using PubMed, Ovid/Medline, and Scopus databases. All English-language studies were included if they proposed or assessed novel interventions developed for Otolaryngology practice during the COVID-19 pandemic. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed.Results:A total of 41 papers met inclusion criteria and were organized into 5 categories ('General Recommendations for Otolaryngologic Surgery’, 'Equipment Shortage Solutions’, 'Airway Procedures’, 'Nasal Endoscopy and Skull Base Procedures’, and 'Otologic Procedures’). Articles were summarized, highlighting the innovations created and evaluated during the COVID-19 pandemic. Creative solutions such as application of topical viricidal agents, make-shift mask filters, three-dimensional (3-D) printable adapters for headlights, aerosol containing separation boxes, and a variety of new draping techniques have been developed to limit the risk of COVID-19 transmission.Conclusions:Persistent risk of COVID-19 exposure remains high. Thus, there is an increased need for solutions that mitigate the risk of viral transmission during office procedures and surgeries, especially given that most COVID-19 positive patients present asymptomatically. This review examines and organizes creative solutions that have been proposed and utilized in the otolaryngology. These solutions have a potential to minimize the risk of viral transmission in the current clinical environment and to create safer outpatient and operating room conditions for patients and healthcare staff.